OptiNose appoints Terry Kohler as CFO; grants 675K share option and 150K RSUs as inducement

OptiNose, Inc.

Terry Kohler appointed CFO effective Oct 7, 2024; previously CFO of Verrica Pharmaceuticals.
Base salary of $450,000/year, target bonus 45% of salary, eligible for annual equity awards.
Received inducement grant: option to purchase 675,000 shares at $0.71/share and 150,000 RSUs, both vesting over 4 years.
One-time special payment of $90,000 payable in March 2025, repayable if employment terminated within 12 months.
Severance: 12 months base salary without cause/good reason; enhanced benefits upon change of control.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Terry Kohler

Chief Financial Officer

OptiNose, Inc.

Effective: 2024-10-07
Filed: October 8, 2024, 7:59 PM ET

On October 7, 2024, OptiNose, Inc. (the “Company”) appointed Terry Kohler as the Company’s Chief Financial Officer.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Terry Kohler was appointed as Chief Financial Officer at OptiNose, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On October 7, 2024, OptiNose, Inc. (the “Company”) appointed Terry Kohler as the Company’s Chief Financial Officer.

View on SEC.gov

Source: SEC EDGAR

accession 0001494650-24-000140

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.